Phase-3 Randomized Controlled Trials on Exclusion of Participants With Kidney Disease in COVID-19

被引：6
|
作者：
Chewcharat, Api [1 ]
Chang, Yuan-Ting [2 ]
Sise, Meghan E. [3 ]
Bhattacharyya, Roby P. [4 ]
Murray, Megan B. [5 ,6 ]
Nigwekar, Sagar U. [3 ]
机构：
[1] Harvard Med Sch, Dept Med, Mt Auburn Hosp, Cambridge, MA USA
[2] Univ Edinburgh, Anne Rowling Regenerat Neurol Clin, Edinburgh, Midlothian, Scotland
[3] Harvard Med Sch, Dept Med, Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02115 USA
[4] Harvard Med Sch, Div Infect Dis, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA
[5] Harvard Med Sch, Depy Global Hlth & Social Med, Boston, MA 02115 USA
[6] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
来源：
KIDNEY INTERNATIONAL REPORTS | 2021年 / 6卷 / 01期
关键词：
D O I：
10.1016/j.ekir.2020.10.010
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：196 / 199
页数：4
相关论文
共 50 条
  • [1] COVID-19 randomized controlled trials in medRxiv and PubMed
    Kataoka, Yuki
    Oide, Shiho
    Ariie, Takashi
    Tsujimoto, Yasushi
    Furukawa, Toshi A.
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 81
  • [2] Paying Participants in COVID-19 Trials
    Largent, Emily A.
    Lynch, Holly Fernandez
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (03): : 356 - 361
  • [3] Placebo-controlled trials with COVID-19 vaccines: participants first
    Dal-Re, Rafael
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2021, 138 : 211 - 212
  • [4] Endpoints used in phase III randomized controlled trials of treatment options for COVID-19
    Desai, Aakash
    Gyawali, Bishal
    [J]. ECLINICALMEDICINE, 2020, 23
  • [5] Transparency and reporting characteristics of COVID-19 randomized controlled trials
    Kapp, Philipp
    Esmail, Laura
    Ghosn, Lina
    Ravaud, Philippe
    Boutron, Isabelle
    [J]. BMC MEDICINE, 2022, 20 (01)
  • [6] Nocebo responses in randomized controlled trials of COVID-19 vaccines
    Lee, Young Ho
    Song, Gwan Gyu
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2022, 60 (01) : 5 - 12
  • [7] Endpoints for randomized controlled clinical trials for COVID-19 treatments
    Dodd, Lori E.
    Follmann, Dean
    Wang, Jing
    Koenig, Franz
    Korn, Lisa L.
    Schoergenhofer, Christian
    Proschan, Michael
    Hunsberger, Sally
    Bonnett, Tyler
    Makowski, Mat
    Belhadi, Drifa
    Wang, Yeming
    Bin Cao
    Mentre, France
    Jaki, Thomas
    [J]. CLINICAL TRIALS, 2020, 17 (05) : 472 - 482
  • [8] Transparency and reporting characteristics of COVID-19 randomized controlled trials
    Philipp Kapp
    Laura Esmail
    Lina Ghosn
    Philippe Ravaud
    Isabelle Boutron
    [J]. BMC Medicine, 20
  • [9] Randomized Controlled Trials on COVID-19 Should Be Accurate and Trustworthy
    Mol, Ben W.
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2022, 106 (01): : 369 - 369
  • [10] Being fair to participants in placebo-controlled COVID-19 vaccine trials
    Rafael Dal-Ré
    Walter Orenstein
    Arthur L. Caplan
    [J]. Nature Medicine, 2021, 27 : 938 - 938
12345